CI
SPRY icon

CX Institutional’s ARS Pharmaceuticals SPRY Stock Holding History

CX Institutional’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Sell
8,390
-500
-6% -$4.3K ﹤0.01% 932
2026
Q1 		$71K Sell
8,890
-100
-1% -$958 ﹤0.01% 914
2025
Q4 		$105K Sell
8,990
-200
-2% -$1.95K ﹤0.01% 843
2025
Q3 		$92K Buy
+9,190
New +$132K ﹤0.01% 836

Other funds holding SPRY

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CX Institutional's SPRY Position: Q2 2026 in Review

CX Institutional reduced its ARS Pharmaceuticals (SPRY) stake by 5.6% in Q2 2026, selling an estimated $4.3K and leaving 8,390 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

CX Institutional first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $105K in Q4 2025. 8 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • CX Institutional held 8,390 shares of ARS Pharmaceuticals worth $67K as of Q2 2026.
  • CX Institutional sold 500 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #932 holding.
  • CX Institutional first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • CX Institutional's ARS Pharmaceuticals position peaked at $105K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.